ESMO-Webinar-series-Taxonomy-Tumour-Agnostic-Therapeutics-1000x250

Application deadline

17 Apr 2024 at 18:30 CEST

Chair’s welcome

I am pleased to extend an invitation for you to join us for an interactive webinar that delves into the development of tissue-agnostic precision oncology therapeutics. This session is one of four ESMO webinars in a series centred around genomics-guided care.

I have the great privilege to host a panel of esteemed professionals for this webinar. Our discourse will not only explore the tissue-agnostic therapeutics approved so far and delivering precision oncology in that regard, but also navigate the running the clinical trials of the future, addressing challenges related to tissue-agnostic classification and the dynamic paradigms of drug development.

The overarching design of our programme aims to discuss the ESMO's new proposal for a taxonomy of tissue-agnostic therapeutics in oncology, including a set of minimum requirements for a therapy to be eligible for tissue-agnostic potential and elaborate the reasons why it is needed.

By contextualising the current landscape of tissue-agnostic therapeutics in oncology and where the future clinical trials will lead us, facilitating expert dialogues, and highlighting key considerations around proposed tissue-agnostic classifier, we aspire to provide a framework with the next steps in domains of research, clinical practice, and policy changes needed for drug development in a tissue-agnostic manner.

Importantly, we will take and discuss questions from the audience to make this webinar interactive and gain feedback from the international oncology community.

I invite you to register and join us all in this new ESMO activity.

Dr. Benedikt Westphalen
Comprehensive Cancer Centre Munich (CCC München), Ludwig Maximilian University Hospital (LMU Klinikum), Munich, Germany

Speakers

Programme

Time	Title	Speaker
5 min	Introduction—Delivering on the Promise of Precision Oncology	Claudia Cardone (Speaker)
10 min	Histology Agnostic Therapeutics: The Story so Far	Vivek Subbiah (Speaker)
10 min	How to Run the Clinical Trials of the Future	Sewanti Limaye (Speaker)
10 min	ESMO Tumour-Agnostic Classifier (ETAC): Why a Taxonomy is Needed?	Benedikt Westphalen (Chair)
20 min	LIVE Q & A	All
5 min	Conclusions	George Pentheroudakis (Co-Chair)

Live viewers of the webinar will be awarded a certificate of attendance and 1 ESMO-MORA category 1 point.

Learning objectives:

To discuss a proposal for a taxonomy of tissue agnostic therapeutics.
To highlight the scientific issues and clinical trial designs pertaining to the development of oncology drugs agnostic of tumour type.
To explore the opportunities and challenges in development of a framework for drug development in a tumour agnostic manner.

Speakers

Programme

Learning objectives:

Supported by

How to Access

You may also be interested in...